Japan’s TTM Plans September Launch Of Novel Blood Analyzer
This article was originally published in PharmAsia News
TTM of Japan says it plans to have ready for the market by September a portable device that provides a new way to analyze blood. The Tokyo-based company said the palm-size analyzer measures eight factors, such as blood glucose, cholesterol and triglycerides related to metabolic syndrome. TTM hopes to sell 10,000 units over the next five years and turn its development attention to versions of tests for liver and kidney functions. (Click here for more - a subscription may be required
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.